GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Austar Lifesciences Ltd (HKSE:06118) » Definitions » ROIC %

Austar Lifesciences (HKSE:06118) ROIC % : 6.84% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Austar Lifesciences ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Austar Lifesciences's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was 6.84%.

As of today (2024-05-03), Austar Lifesciences's WACC % is 6.54%. Austar Lifesciences's ROIC % is -0.62% (calculated using TTM income statement data). Austar Lifesciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Austar Lifesciences ROIC % Historical Data

The historical data trend for Austar Lifesciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Austar Lifesciences ROIC % Chart

Austar Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 3.87 10.12 7.06 -0.62

Austar Lifesciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.31 5.49 8.26 -7.50 6.84

Competitive Comparison of Austar Lifesciences's ROIC %

For the Medical Devices subindustry, Austar Lifesciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Austar Lifesciences's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Austar Lifesciences's ROIC % falls into.



Austar Lifesciences ROIC % Calculation

Austar Lifesciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-9.859 * ( 1 - -1.1% )/( (1728.351 + 1503.181)/ 2 )
=-9.967449/1615.766
=-0.62 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2667.567 - 773.798 - ( 165.418 - max(0, 1518.47 - 2011.211+165.418))
=1728.351

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2361.438 - 668.197 - ( 190.06 - max(0, 1288.129 - 1721.41+190.06))
=1503.181

Austar Lifesciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=102.258 * ( 1 - -4.24% )/( (1613.293 + 1503.181)/ 2 )
=106.5937392/1558.237
=6.84 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2518.125 - 767.135 - ( 137.697 - max(0, 1461.114 - 1875.363+137.697))
=1613.293

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2361.438 - 668.197 - ( 190.06 - max(0, 1288.129 - 1721.41+190.06))
=1503.181

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Austar Lifesciences  (HKSE:06118) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Austar Lifesciences's WACC % is 6.54%. Austar Lifesciences's ROIC % is -0.62% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Austar Lifesciences ROIC % Related Terms

Thank you for viewing the detailed overview of Austar Lifesciences's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Austar Lifesciences (HKSE:06118) Business Description

Traded in Other Exchanges
Address
No. 1018, Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess Systems; Clean Room and Automation Control and Monitoring Systems; Powder and Solid Systems; Good Manufacturing Practice (GMP) Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.

Austar Lifesciences (HKSE:06118) Headlines

No Headlines